Navigation Links
GenVec Reports Third Quarter 2009 Financial Results
Date:11/5/2009

GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) today announced its financial results for the third quarter ended September 30, 2009. GenVec reported a net loss of $3.6 million ($0.04 per share) for the three months ended September 30, 2009 compared to a net loss of $6.8 million ($0.08 per share) in the comparable quarter of 2008. For the nine months ended September 30, 2009, GenVec's net loss was $14.1 million ($0.15 per share), compared to a net loss of $19.6 million ($0.24 per share) for the nine months ended September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

Revenues for the three-month and nine-month periods ended September 30, 2009 were $2.9 million and $10.5 million, respectively, compared to revenues of $4.2 million and $11.8 million in the comparable prior year periods. For each period in 2009 we experienced decreased revenue under the FMD program due mainly to the scope of work performed compared to the prior year periods. We also had lower revenue under the malaria program for the nine-month period ended September 30, 2009 due mainly to the work performed under the new contract which did not begin until the second quarter of 2009. The decreases noted above were offset by an increase in revenue associated with our HIV program in the nine-month period ended September 30, 2009 due mainly to increased research, assay, and process development efforts as compared to the comparable prior year period.

Operating expenses were $6.5 million and $24.3 million for the three-month and nine-month periods ended September 30, 2009, respectively, representing decreases of 42 percent and 24 percent as compared to $11.2 million and $32.0 million in the comparable prior year perio
'/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
(Date:5/20/2013)... With bed bugs' presence come problems in ... bugs need to be eliminated, one must make sure that ... health. And so to help bed bug sufferers get that ... of bed bugs without using harmful pesticides. In it, ... called Bed Bug Bully. , According to My Cleaning Products, ...
(Date:5/20/2013)... HILL, N.C. , May 20, 2013 /PRNewswire/ ... company focused on developing differentiated antibiotics to meet ... infections, today announced that it presented data at ... in Philadelphia demonstrating the ... levofloxacin in Cempra,s prior Phase 2 clinical trial ...
(Date:5/20/2013)... , May 20, 2013 Rhythm announced today ... of RM-131, the company,s novel ghrelin agonist for the ... The trial demonstrated that RM-131 significantly accelerates early gastric ... 1 diabetic patients with diabetic gastroparesis. The findings were ... Orlando and recently published in ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3
... SANTA CLARA, Calif., Oct. 10 Finesse Solutions, ... life science process,applications, is pleased to announce improvements ... and transmitters even easier. The E-Store,can be found ... can now easily purchase bioprocess sensors and accessories,on-line, ...
... ... People, INDIANAPOLIS, Oct. ... it has made the list of Top 20,biopharmaceutical employers, according to the ... in the biotechnology, biopharmaceutical, pharmaceutical and,related industries. This year Lilly ranks number ...
... Technologies announced,today that David E. Kandzari, MD, ... System" during the Drug-Eluting Stent Summit at ... on October 13, 2008. The MiStent(TM), a ... polymer coating that,delivers the potential therapeutic benefits ...
Cached Biology Technology:Lilly Recognized as One of the World's Top Biopharmaceutical Employers 2
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... Biology (SDB) 72nd Annual Meeting in Cancun, Mexico ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... shown a gene involved in neurodegenerative disease also plays ... circadian clock. , In a study of the ... Ataxin-2, keeps the clock responsible for sleeping and waking ... of the fruit fly,s sleep-wake cycle is disturbed, making ... fly. , The discovery is particularly interesting because ...
(Date:5/16/2013)... The relationship between the heritable risk for schizophrenia ... Schizophrenia is commonly associated with cognitive impairments that ... reduced IQ may be linked to the risk ... may precede the onset of schizophrenia symptoms. Also, ... of people diagnosed with schizophrenia. , In a ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Genetic risk for schizophrenia is connected to reduced IQ 2
... Blacksburg, Va. Researchers have unveiled the evolutionary ... three species of Agrobacterium. A comprehensive comparison of ... of other bacteria suggests a general model for ... Agrobacteria are members of the Rhizobiaceae family, which ...
... and a fast bite spelled doom for bony fishes during ... a new study to be published March 31, 2009, in ... Today, those same features characterize large predatory bony ... decline and at risk of extinction themselves, said Matt Friedman, ...
... developed at the University of California, Davis to treat ... human clinical trials to evaluate its efficacy. ... is "a first-in-class drug which may treat a suite ... Hammock, who with UC Berkeley cell biologist Sarjeet Gill ...
Cached Biology News:Evolutionary origin of bacterial chromosomes revealed 2Study unravels why certain fishes went extinct 65 million years ago 2Study unravels why certain fishes went extinct 65 million years ago 3UC Davis bench-to-bedside research: Promising treatment in clinical trials 2UC Davis bench-to-bedside research: Promising treatment in clinical trials 3UC Davis bench-to-bedside research: Promising treatment in clinical trials 4UC Davis bench-to-bedside research: Promising treatment in clinical trials 5
...
... to quantitate double-stranded DNA (dsDNA) in solution, even ... this kit, DNA is stained with Hoechst 33258 ... or other fluorometer. The kit quantitates dsDNA in ... 5 micrograms per ml and contains Hoechst 33258, ...
... of colony stimulating factors for assays of ... blood and fetal liver. Suitable for ... and CFU-GEMM when added to methylcellulose at ... of erythropoietin. Will also support growth ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
Biology Products: